Products
News
Resources
Contact
Language
简体中文
繁體中文
English
日本語
한국어
Tiếng Việt
Overview
Latest
Regional
Industry
Featured
Multimedia
Other Languages
Public Company News
All
APAC
Global
All
APAC
Global
All
APAC
Global
All
APAC
Global
{{toptitleLeft}}
{{toptitleRight}}
{{selectTitle}}
{{toptitleLeft}}
{{index}}
{{select_list_per.name}}
Time
{{showName}}
{{weixin_name}}
X
{{listname}}
Loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.headline}}
{{storydata.create_time}}
{{storydata.headline}}
{{storydata.create_time}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{theme.pcom_theme_name}}
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{theme.pcom_theme_name}}
loading
The End
Network Errors Please Retry
Telix Successfully Prices A$650 Million Convertible Bonds
2024-07-24 07:51
Telix Announces A$600 Million Convertible Bonds Offering
2024-07-23 16:35
Telix Pharmaceuticals Q2 2024 Revenue and Business Highlights, Guidance Upgrade
2024-07-18 07:17
Telix Welcomes CMS Proposal to Improve Payment for Specialised Diagnostic Radiopharmaceuticals
2024-07-11 08:21
Telix Completes TLX250-CDx (Zircaix®) BLA Submission for Kidney Cancer Imaging
2024-06-03 09:08
Telix Announces Positive rPFS Data from ProstACT SELECT Trial of TLX591 rADC Therapy Candidate in Prostate Cancer
2024-05-31 07:19
Telix Submits NDA for New Prostate Cancer Imaging Agent
2024-05-27 07:21
Telix Completes Proof-of-Concept Study of TLX592 Targeted Alpha Therapy in Prostate Cancer
2024-05-21 07:58
Q1 2024 Revenue and Business Update
2024-04-17 15:05
TLX101-CDx (Pixclara™) Granted FDA Fast Track Designation
2024-04-16 06:42
World First Use of Lightpoint's SENSEI® Drop-In Gamma Probe in Bladder Cancer Surgery Performed in Spain
2024-03-27 05:59
QDOSE® Platform Partnership for Personalised Dosimetry in Radiopharmaceutical Therapy
2024-03-19 05:19
Appointment of Dr Darren Patti to Group Chief Operating Officer
2024-03-12 05:44
Telix to Acquire ARTMS, Inc. and its Advanced Isotope Production Platform
2024-03-05 07:01
Telix Expands U.S. Development and Manufacturing Infrastructure with Acquisition of IsoTherapeutics
2024-02-27 05:55
Telix 2023 Full Year Results: Inaugural Profit Achieved, Strong Revenue Growth Underpins Investment in Late-stage Pipeline
2024-02-22 17:31
Telix Signs Agreement to Acquire QSAM Biosciences and Its Bone Cancer Targeting Platform
2024-02-08 06:11
Telix Highlights Presentations at Upcoming ASCO Genitourinary Cancers Symposium (ASCO GU 2024)
2024-01-22 19:00
Telix to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2024-01-04 06:20
Telix Submits Biologics License Application (BLA) for TLX250-CDx (Zircaix™) for Imaging of Kidney Cancer
2023-12-19 05:44
1
2
3
4
5
7